This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCormack, J. G. Articles by Lopaschuk, G. D. Search for Related Content PubMed PubMed Citation Articles by McCormack, J. G. Articles by Lopaschuk, G. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETANILIDE GLUCOSE Medline Plus Health Information Cardiomyopathy

(Circulation. 1996;93:135-142.)
© 1996 American Heart Association, Inc.

Articles

Ranolazine Stimulates Glucose Oxidation in Normoxic, Ischemic, and Reperfused Ischemic Rat Hearts

James G. McCormack, PhD, DSC; Rick L. Barr; Andrew A. Wolff, MD; Gary D. Lopaschuk, PhD

From the Departments of Pediatrics and Pharmacology, University of Alberta, Edmonton, Canada (R.L.B., G.D.L.), Syntex Medical Research, Palo Alto, Calif (A.A.W.), and the Department of Pharmacology, Syntex Research Centre, Heriot-Watt University Research Park, Edinburgh, Scotland (J.G.M.).

Correspondence to Prof G.D. Lopaschuk, Cardiovascular Disease Research Group, Departments of Pediatrics and Pharmacology, 423 Heritage Medical Research Bldg, University of Alberta, Edmonton, T6G 2S2, Canada. E-mail glopasch@gpu.srv.ualberta.ca.

Background Ranolazine is a novel antianginal agent that may reduce symptoms without affecting hemodynamics and has shown cardiac antiischemic effects in in vivo and in vitro models. In one study it increased active pyruvate dehydrogenase (PDHa). Other agents that increase PDHa and so increase glucose and decrease fatty acid (FA) oxidation are beneficial in ischemic-reperfused hearts. Effects of ranolazine on glucose and palmitate oxidation and glycolysis were assessed in isolated rat hearts.

Methods and Results Working hearts were perfused with Krebs-Henseleit buffer plus 3% albumin under normoxic conditions and on reperfusion after 30-minute no-flow ischemia and under conditions designed to give either low [low (Ca) (1.25 mmol/L), high [FA] (1.2 mmol/L palmitate); with/without insulin] or high (2.5 mmol/L Ca, 0.4 mmol/L palmitate; with/without pacing) glucose oxidation rates; Langendorff-perfused hearts (high Ca, low FA) were subjected to varying degrees of low-flow ischemia. Glycolysis and glucose oxidation were measured with the use of [5-³H/U-¹⁴C]-glucose and FA oxidation with the use of [1-¹⁴C]- or [9,10-³H]-palmitate. In working hearts, 10 µmol/L ranolazine significantly increased glucose oxidation 1.5-fold to 3-fold under conditions in which the contribution of glucose to overall ATP production was low (low Ca, high FA, with insulin), high (high Ca, low FA, with pacing), or intermediate. In some cases, reductions in FA oxidation were seen. No substantial changes in glycolysis were noted with/without ranolazine; rates were 10-fold glucose oxidation rates, suggesting that pyruvate supply was not limiting. Insulin increased basal glucose oxidation and glycolysis but did not alter ranolazine responses. In normoxic Langendorff hearts (high Ca, low FA; 15 mL/min), all basal rates were lower compared with working hearts, but 10 µmol/L ranolazine similarly increased glucose oxidation; ranolazine also significantly increased it during flow reduction to 7, 3, and 0.5 mL/min. Ranolazine did not affect baseline contractile or hemodynamic parameters or O₂ use. In reperfused ischemic working hearts, ranolazine significantly improved functional outcome, which was associated with significant increases in glucose oxidation, a reversal of the increased FA oxidation seen in control reperfusions (versus preischemic), and a smaller but significant increase in glycolysis.

Conclusions Beneficial effects of ranolazine in cardiac ischemia/reperfusion may be due, at least in part, to a stimulation of glucose oxidation and a reduction in FA oxidation, allowing improved ATP/O₂ and reduction in the buildup of H⁺, lactate, and harmful fatty acyl intermediates.

Key Words: glucose • glycolysis • ischemia • fatty acids • reperfusion

This article has been cited by other articles:

				L. H. Opie and J. Knuuti The adrenergic-Fatty Acid load in heart failure. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646. [Abstract] [Full Text] [PDF]

				H. Hwang, J. M. Arcidi Jr, S. L. Hale, B. Z. Simkhovich, L. Belardinelli, A. K. Dhalla, J. C. Shryock, and R. A. Kloner Ranolazine as an Adjunct to Cardioplegia: A Potential New Therapeutic Application Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2009; 14(2): 125 - 133. [Abstract] [PDF]

				T. Doenst, H. Bugger, M. Schwarzer, G. Faerber, M. A. Borger, and F. W. Mohr Three good reasons for heart surgeons to understand cardiac metabolism Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 862 - 871. [Abstract] [Full Text] [PDF]

				R. M. Witteles and M. B. Fowler Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102. [Abstract] [Full Text] [PDF]

				S. L. Hale, J. A. Leeka, and R. A. Kloner Improved Left Ventricular Function and Reduced Necrosis after Myocardial Ischemia/Reperfusion in Rabbits Treated with Ranolazine, an Inhibitor of the Late Sodium Channel J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 418 - 423. [Abstract] [Full Text] [PDF]

				L Belardinelli, J C Shryock, and H Fraser Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine Heart, July 1, 2006; 92(suppl_4): iv6 - iv14. [Abstract] [Full Text] [PDF]

				C. Marx and M. Sweeney Mechanism of action of ranolazine. Arch Intern Med, June 26, 2006; 166(12): 1325 - 1326. [Full Text] [PDF]

				M. J Tafreshi and E. Fisher Ranolazine: A New Approach to Management of Patients with Angina Ann. Pharmacother., April 1, 2006; 40(4): 689 - 693. [Abstract] [Full Text] [PDF]

				H. Taegtmeyer Cardiac Metabolism as a Target for the Treatment of Heart Failure Circulation, August 24, 2004; 110(8): 894 - 896. [Full Text] [PDF]

				B. R. Chaitman, S. L. Skettino, J. O. Parker, P. Hanley, J. Meluzin, J. Kuch, C. J. Pepine, W. Wang, J. J. Nelson, D. A. Hebert, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1375 - 1382. [Abstract] [Full Text] [PDF]

				L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]

				L. H. Opie Angina Pectoris: The Evolution of Concepts Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S3 - S9. [PDF]

				U. Thadani Current Medical Management of Chronic Stable Angina Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S11 - S29. [Abstract] [PDF]

				W. C. Stanley Myocardial Energy Metabolism During Ischemia and the Mechanisms of Metabolic Therapies Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S31 - S45. [Abstract] [PDF]

				B. R. Chaitman Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S47 - S64. [Abstract] [PDF]

				B. R. Chaitman, C. J. Pepine, J. O. Parker, J. Skopal, G. Chumakova, J. Kuch, W. Wang, S. L. Skettino, and A. A. Wolff Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic Angina: A Randomized Controlled Trial JAMA, January 21, 2004; 291(3): 309 - 316. [Abstract] [Full Text] [PDF]

				A. MacInnes, D. A. Fairman, P. Binding, J. a. Rhodes, M. J. Wyatt, A. Phelan, P. S. Haddock, and E. H. Karran The Antianginal Agent Trimetazidine Does Not Exert Its Functional Benefit via Inhibition of Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase Circ. Res., August 8, 2003; 93 (3): e26 - e32. [Abstract] [Full Text] [PDF]

				G. D. Lopaschuk, R. Barr, P. D. Thomas, and J. R.B. Dyck Beneficial Effects of Trimetazidine in Ex Vivo Working Ischemic Hearts Are Due to a Stimulation of Glucose Oxidation Secondary to Inhibition of Long-Chain 3-Ketoacyl Coenzyme A Thiolase Circ. Res., August 8, 2003; 93 (3): e33 - e37. [Abstract] [Full Text] [PDF]

				G. D. Lopaschuk and M. Marzilli Mode of Action of Trimetazidine and Other New Metabolic Agents in the Treatment of Ischemic Heart Disease Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 91 - 96. [PDF]

				C.-L. M. Soltys, L. Buchholz, M. Gandhi, A. S. Clanachan, K. Walsh, and J. R. B. Dyck Phosphorylation of cardiac protein kinase B is regulated by palmitate Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1056 - H1064. [Abstract] [Full Text] [PDF]

				H. Taegtmeyer, P. McNulty, and M. E. Young Adaptation and Maladaptation of the Heart in Diabetes: Part I: General Concepts Circulation, April 9, 2002; 105(14): 1727 - 1733. [Full Text] [PDF]

				D.V. Cokkinos Can metabolic manipulation reverse myocardial dysfunction? Eur. Heart J., December 1, 2001; 22(23): 2138 - 2139. [PDF]

				R. Ramasamy, J. A. Payne, J. Whang, S. R. Bergmann, and S. Schaefer Protection of ischemic myocardium in diabetics by inhibition of electroneutral Na+-K+-2Cl{-} cotransporter Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H515 - H522. [Abstract] [Full Text] [PDF]

				M. Taniguchi, C. Wilson, C. A. Hunter, D. J. Pehowich, A. S. Clanachan, and G. D. Lopaschuk Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1762 - H1769. [Abstract] [Full Text] [PDF]

				H. Taegtmeyer Metabolism--the lost child of cardiology J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1386 - 1388. [Full Text] [PDF]

				N. A. Trueblood, R. Ramasamy, L. F. Wang, and S. Schaefer Niacin protects the isolated heart from ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, August 1, 2000; 279(2): H764 - H771. [Abstract] [Full Text] [PDF]

				P. H. McNulty, G. W. Cline, J. M. Whiting, and G. I. Shulman Regulation of myocardial [13C]glucose metabolism in conscious rats Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H375 - H381. [Abstract] [Full Text] [PDF]

				P. F. Kantor, A. Lucien, R. Kozak, and G. D. Lopaschuk The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase Circ. Res., March 17, 2000; 86(5): 580 - 588. [Abstract] [Full Text] [PDF]

				E. P Brass and W. R Hiatt Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease Vascular Medicine, February 1, 2000; 5(1): 55 - 59. [Abstract] [PDF]

				Q. Liu, A. S. Clanachan, and G. D. Lopaschuk Acute effects of triiodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts Am J Physiol Endocrinol Metab, September 1, 1998; 275(3): E392 - E399. [Abstract] [Full Text] [PDF]

				J. Dizon, D. Burkhoff, J. Tauskela, J. Whang, P. Cannon, and J. Katz Metabolic inhibition in the perfused rat heart: evidence for glycolytic requirement for normal sodium homeostasis Am J Physiol Heart Circ Physiol, April 1, 1998; 274(4): H1082 - H1089. [Abstract] [Full Text] [PDF]

				G. D. Lopaschuk and W. C. Stanley Glucose Metabolism in the Ischemic Heart Circulation, January 21, 1997; 95(2): 313 - 315. [Full Text]

				B. Liu, A. S. Clanachan, R. Schulz, and G. D. Lopaschuk Cardiac Efficiency Is Improved After Ischemia by Altering Both the Source and Fate of Protons Circ. Res., November 1, 1996; 79(5): 940 - 948. [Abstract] [Full Text]

				H. S. Leong, M. Grist, H. Parsons, R. B. Wambolt, G. D. Lopaschuk, R. Brownsey, and M. F. Allard Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact? Am J Physiol Endocrinol Metab, May 1, 2002; 282(5): E1039 - E1045. [Abstract] [Full Text] [PDF]